Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Gastrointestinal
13:14

Memorial Sloan Kettering Cancer Center

Organ Preservation in Rectal Cancer: Neoadjuvant Short-Course RT vs. Long-Course CRT

FEATURING Paul Romesser
  • 76 views
  • October 21, 2024
  • 1
13:50

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: DESTINY-Gastric03 - T-DXd Monotherapy and Combinations in Pts With Adv/Metastatic HER2+ Esophageal, Gastric, or GEJ Adenocarcinoma

FEATURING Yelena Janjigian
  • 125 views
  • October 2, 2024
  • 1
04:39

Insights from 2024 ASCO® GI Annual Meeting

ASCO® GI 2024 Insights: "PROOF 301 Trial - Oral FGFR Inhibitor Infigratinib vs. Gemcitabine + Cisplatin in Patients With Advanced Cholangiocarcinoma With an FGFR2 Gene Fusion/Rearrangement"

FEATURING Ghassan Abou-Alfa
  • 172 views
  • January 31, 2024
  • 3
06:31

ecancer

CheckMate 649 Trial Biomarker Analyses of Nivo + Ipi vs. Chemo for Patients With GC/GEJC/EAC

FEATURING Yelena Y. Janjigian
  • 231 views
  • June 21, 2023
  • 1
31:25

Total Health

Updates in Rectal Cancer: Optimizing Response, Preserving the Organ, and Paradigm Shifting

FEATURING Joshua Smith
  • 1,203 views
  • March 1, 2023
  • 12
10:36

CE Concepts

Pathophysiologic Foundations in HCC/BTC: Immune System as a Therapeutic Target

FEATURING James Harding
  • 78 views
  • February 13, 2023
11:02

ASCO GI 2023 Conference Coverage

ASCO GI 2023 3-Year Follow-Up From CheckMate 649: Nivo + Chemo vs. Chemo as 1L Treatment for Advanced GC/GEJC/EAC

FEATURING Yelena Y. Janjigian
  • 598 views
  • February 10, 2023
  • 5
07:43

ASCO GI 2023 Conference Coverage

ASCO GI 2023 ctDNA for Response Assessment in Patients With Anal Cancer Treated With Definitive CRT

FEATURING Janet Alvarez
  • 130 views
  • January 26, 2023
06:16

ASCO GI 2023 Conference Coverage

ASCO GI 2023 on Organ Preservation and Total Neoadjuvant Therapy for Rectal Cancer: Investigating Long-Course CRT vs. Short-Course Radiation Therapy

FEATURING Paul Romesser
  • 360 views
  • January 25, 2023
38:04

Debbie's Dream Foundation

Advances in IO and Targeted Agents in Gastroesophageal Cancer

FEATURING David Ilson
  • 616 views
  • October 21, 2022
  • 7
05:41

ecancer

An Overview of Treatment Advances in Gastric Cancer

FEATURING David Ilson
  • 327 views
  • September 7, 2022
  • 1
04:07

ecancer

ASCO 2022: Single-Agent PD-1 Blockade as Curative-Intent Treatment in dMMR Locally Advanced Rectal Cancer

FEATURING Andrea Cercek
  • 64 views
  • June 23, 2022
09:42

ASCO 2022 Conference Coverage

ASCO 2022 Targeting HER2 Mutation-Positive Advanced Biliary Tract Cancers With Neratinib: Final Results From the Phase 2 SUMMIT Basket Trial

FEATURING James Harding
  • 91 views
  • June 15, 2022
58

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Targeting HER2 Mutation-Positive Advanced Biliary Tract Cancers With Neratinib: Final Results From the Phase 2 SUMMIT Basket Trial

FEATURING James Harding
  • 16 views
  • June 15, 2022
06:42

ASCO 2022 Conference Coverage

ASCO 2022 on PROOF 301 Trial: Updates on Infigratinib vs. Gemcitabine + Cisplatin in Advanced Cholangiocarcinoma With a FGFR2 Gene Fusion/Rearrangement

FEATURING Ghassan Abou-Alfa
  • 1,149 views
  • June 7, 2022
  • 7
23

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Updates on Infigratinib vs. Gemcitabine + Cisplatin in Advanced Cholangiocarcinoma With a FGFR2 Gene Fusion/Rearrangement: PROOF 301 Trial

FEATURING Ghassan Abou-Alfa
  • 104 views
  • June 7, 2022
07:48

ecancer

Tremelimumab and Durvalumab as 1L in Unresectable HCC: Phase 3 HIMALAYA Trial

FEATURING Ghassan Abou-Alfa
  • 257 views
  • April 13, 2022
  • 1
20:26

Collaborative Group of the Americas for Inherited Gastrointestinal Cancers

Incidental Findings From Somatic Testing and Implications for Hereditary GI Cancers

FEATURING Zsofia Stadler
  • 145 views
  • February 23, 2022
  • 1
08:15

ASCO GI 2022 Conference Coverage

ASCO GI 2022 on a Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis in CheckMate 649: Nivo + Chemo vs. Chemo as 1L Treatment for Advanced GC/GEJC/EAC

FEATURING Ryan Sugarman
  • 433 views
  • February 3, 2022
05:49

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on the Dose-Escalation & Dose-Expansion Study of T-DXd Monotherapy and Combinations in Advanced /Metastatic HER2+ GC/GEJA: DESTINY-Gastric03

FEATURING Yelena Y. Janjigian
  • 230 views
  • February 1, 2022
09:30

Memorial Sloan Kettering Cancer Center

ESMO 2021 Update on Nivo + Chemo or Ipi vs. Chemo as 1L Treatment in Advanced GC/GEJC/EAC: CheckMate 649 Study

FEATURING Yelena Y. Janjigian
  • 212 views
  • October 11, 2021
  • 1
07:44

Memorial Sloan Kettering Cancer Center

ESMO 2021 Abstract Review on Genomic Landscape of Late-Stage Gastric Cancer

FEATURING Yelena Y. Janjigian
  • 204 views
  • September 23, 2021
16:43

Debbie's Dream Foundation

Gastric Cancer: Advances in Systemic Therapy

FEATURING David Ilson
  • 117 views
  • September 21, 2021
07:10

2021 ASCO Virtual Direct™ Highlights

2021 ASCO CRC Updates: 1L Pembro vs. Chemo, Maintenance Chemo, 2L and Beyond

FEATURING Louise Connell
  • 64 views
  • August 23, 2021
09:50

Memorial Sloan Kettering Cancer Center

1L Treatment Updates for Advanced GE/GEJ Cancers: OS Data for Nivo+Ipi vs. Nivo+Chemo vs. Chemo in Gastric/GEJ Cancer, FDA Approval of Pembro for HER2+ Gastric Cancer

FEATURING Yelena Janjigian
  • 36 views
  • May 17, 2021
21:21

Memorial Sloan Kettering Cancer Center

Frontline Management of Advanced GEJ Cancers: Will 5FU/Oxaliplatin + Nivo Become the New SoC? Does Adjuvant Nivo Show DFS Benefit?

FEATURING Yelena Y. Janjigian
  • 414 views
  • March 4, 2021
  • 2
11:00

Memorial Sloan Kettering Cancer Center

BRAF Alterations in Advanced CRC: How Common Are V600E Mutations? How Does Growth Signaling Work?

FEATURING Rona Yaeger
  • 175 views
  • January 5, 2021
  • 1
17:05

Memorial Sloan Kettering Cancer Center

Liver-Directed Therapy for mCRC: What Is the Goal, When to Use and How? How Does HAI Therapy Work? Is Chemo Still the 1st Choice?

FEATURING Andrea Cercek
  • 207 views
  • January 5, 2021
  • 1
13:27

2020 Virtual ESMO Review

2020 ESMO Update on mPDAC: Does the Addition of Dual Immune Checkpoint Inhibitors to Gem and Nab-p Result in Improved OS, PFS, or ORR?

FEATURING Louise Connell
  • 229 views
  • November 4, 2020
  • 1
08:07

2020 Virtual ESMO Review

2020 ESMO Update on Metastatic Pancreatic Cancer: What Does the QoliXane Trial Data Suggest on Time to Deterioration of QoL in Patients Treated With 1L Nab-Paclitaxel?

FEATURING Louise Connell
  • 64 views
  • November 4, 2020
11:33

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Locoregional CRC: 3 vs. 6 Months of Adjuvant Oxaliplatin + Fluoropyrimidine - Is There a Difference in 5 yr OS?

FEATURING Louise Connell
  • 395 views
  • July 14, 2020
  • 2
09:21

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced CRC: Should Pembrolizumab Be The New SoC as First-line Therapy in Patients With MSI-H mCRC?

FEATURING Louise Connell
  • 499 views
  • July 14, 2020
  • 2
14:43

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced CRC: Is Recently FDA Approved Encorafenib + Cetuximab a New SoC for Previously Treated BRAF V600E-mutant mCRC? Can T-DXd Be an Option for HER2+ Disease?

FEATURING Louise Connell
  • 190 views
  • July 14, 2020
  • 1
22:02

Memorial Sloan Kettering Cancer Center

The Role of Modern RT Techniques in Management of Esophagogastric Cancer: IMRT, Protons, Abscopal Effect, and Beyond

FEATURING Abraham Wu
  • 100 views
  • September 27, 2019
18:32

Memorial Sloan Kettering Cancer Center

Advanced Surgical Techniques for Early Stage Esophagogastric Cancer: Endotherapy vs. Esophagectomy

FEATURING Daniela Molena
  • 32 views
  • September 24, 2019
20:17

Memorial Sloan Kettering Cancer Center

Current and Future Personalized Systemic Targets in Esophagogastric Cancer: Anti-HER2, Anti-VEGF, TAS-102, and Claudin 18.2

FEATURING Geoffrey Ku
  • 288 views
  • September 24, 2019
  • 1